Ardelyx Stock Plummets As Review Period For Tenapanor US Application Pushed By 3 Months

  • The FDA has extended the Prescription Drug User Fee Act (PDUFA) date for Ardelyx Inc's ARDX tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.
  • The agency asked the company to submit additional analyses to help the FDA better understand the clinical data in light of tenapanor's novel mechanism of action as compared to approved therapies.
  • In response, the company submitted the requested analyses, resulting in an extension of the PDUFA date by three months to July 29, 2021.
  • Price Action: ARDX shares drop 19% at $6.83 in the premarket session on the last check Friday.

Posted In: BriefsChronic Kidney DiseaseBiotechNewsHealth CareSmall CapFDAGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.